Loading stock data…
Immuron Limited (IMRN)
$1.84+0.04 (+2.22%)
Market ClosedLast close Sep 8
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immuron Limited in the Healthcare sector is trading at $1.84 with a market capitalization of $9M. Wall Street consensus targets $4.03 (1 analysts), implying a +119.3% move over the next 12 months. The stock is currently 23% below its 52-week high of $2.39, remaining 78.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +119.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
4.11M
Recent News
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S
Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement
Immuron (NASDAQ:IMRN) has secured exclusive U. S.
Immuron (IMRN) Struggles After Announcing Trial Results
We recently published 7 Best ASX Stocks to Buy Right Now. Immuron Limited (NASDAQ:IMRN) is one of the best ASX stocks. Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines. Its shares were dealt a hefty setback on Wednesday when they closed 25.8% lower after […]